US PTAB Patent Cases
8,722 decisions indexed
Page 191 of 291 · 8,722 total
Genius Sports Ltd. v.SportsCastr Inc.
The PTAB issued a Final Written Decision finding all nine challenged claims unpatentable over combinations of prior art references (Ellis, Spivey, Herzog). The Board relied heavily on the combination of Ellis and Spivey to establish obviousness for Claim 1, particularly regarding low-latency data delivery via uniquely addressable event sockets.
Genius Sports Ltd. v.SportsCastr Inc.
The PTAB found that claims 19-25 and 27-30 of the '687 patent were unpatentable over a combination of Ellis and Spivey, based on obviousness (Ground 1). The Board rejected an alternative ground involving Herzog, finding no motivation to combine those references.
Genius Sports Ltd. v.SportsCastr Inc.
The PTAB found claims 1-7 unpatentable over a combination of Ellis, Spivey, and Herzog, concluding that the claimed live video streaming system was obvious to a POSA. The Board specifically held that Spivey's topic queues satisfy the definition of an 'event socket.'
Biofrontera Incorporated et al. v.Sun Pharmaceutical Industries, Inc.
The PTAB has sent a Director Review request to Biofrontera in IPR2024-01312, limiting the petitioner’s response to 15 pages and prohibiting new evidence. The petitioner must respond within five business days.
Biofrontera Incorporated et al. v.Sun Pharmaceutical Industries, Inc.
Sun Pharmaceutical seeks Director Review to overturn a PTAB decision that found several claims of its photodynamic‑therapy device patent unpatentable, arguing the Board mis‑constructed key claim terms and ignored ITC findings.
Biofrontera Incorporated et al. v.Sun Pharmaceutical Industries, Inc.
Biofrontera’s petition to overturn the PTAB’s obviousness finding on its photodynamic‑therapy illumination patent was rejected. The Board affirmed that the agreed‑upon claim construction was applied and that the prior‑art combination renders the claims obvious. The Director’s request for review was denied.
Biofrontera Incorporated et al. v.Sun Pharmaceutical Industries, Inc.
Biofrontera has filed an IPR petition challenging Sun Pharmaceutical’s U.S. Patent 11,697,028 covering photodynamic therapy illumination devices, asserting obviousness over Lundahl, Larsen, and Bansal references.
Biofrontera Incorporated et al. v.Sun Pharmaceutical Industries, Inc.
Biofrontera's IPR challenge against Sun Pharmaceutical regarding photodynamic therapy illuminators was instituted by the PTAB. The Board found a reasonable likelihood of prevailing on obviousness grounds over Lundahl and Larsen, focusing on combining prior art elements for flexible device design.
Biofrontera Incorporated et al. v.Sun Pharmaceutical Industries, Inc.
The PTAB found all challenged claims unpatentable by a preponderance of the evidence. The Petitioner successfully argued that combining prior art references (Lundahl and Larsen) rendered the illuminator system obvious to a Person Having Ordinary Skill in the Art (POSITA).
Geneoscopy, Inc. v.Exact Sciences Corporation
Geneoscopy challenges Exact Sciences’ colorectal‑cancer fecal‑testing patent (U.S. 11,970,746) in an IPR. The petitioner’s response argues that the patent owner waived any new claim‑construction arguments and that the Board’s obviousness findings are well‑supported. The document urges the Director to deny the request for review.
Geneoscopy, Inc. v.Exact Sciences Corporation
The PTAB held that all 20 claims of Exact Sciences' 11,634,781 patent are obvious over prior art, rendering them unpatentable. Geneoscopy successfully proved the combination of existing fecal screening methods made the claims non‑inventive.
Geneoscopy, Inc. v.Exact Sciences Corporation
Exact Sciences seeks Director Review of a PTAB Final Written Decision that found its at‑home stool‑based colorectal cancer screening patent unpatentable. The request argues the petitioner’s inconsistent claim constructions and reliance on contradictory expert testimony violated Board policy.
Geneoscopy, Inc. v.Exact Sciences Corporation
Geneoscopy has filed an IPR petition seeking to invalidate claims 1‑4 and 12‑19 of Exact Sciences’ ’746 patent on the grounds of obviousness and lack of novelty, citing multiple prior‑art references.
Microsoft Corporation v.Proxense, LLC
Microsoft has filed an IPR petition seeking to invalidate 22 claims of Proxense’s biometric authentication patent, arguing obviousness over the Ludtke and Kon references and asserting that discretionary denial is improper.
Microsoft Corporation v.Proxense, LLC
Microsoft has filed a petition for inter partes review of Proxense’s ’730 biometric authentication patent, asserting obviousness over the Ludtke and Kon references and arguing that discretionary denial is unwarranted. The petition seeks institution of the IPR and cancellation of all challenged claims.
Microsoft Corporation v.Proxense, LLC
Microsoft has filed an IPR petition seeking to invalidate 15 claims of Proxense’s ’905 biometric authentication patent, arguing obviousness over prior art Ludtke and Kon and opposing discretionary denial.
Geneoscopy, Inc. v.Exact Sciences Corporation
The PTAB instituted an IPR in a colorectal cancer screening case, finding a reasonable likelihood that Geneoscopy's challenged claims are unpatentable. The Board accepted the petitioner's argument that combinations of various prior art references teach every limitation of the claims with a reason for combination.
Microsoft Corporation v.Proxense, LLC
The PTAB denied Microsoft's request to institute Inter Partes Review (IPR) against Proxense's patent 8,886,954. The denial was based on a procedural condition that required prior non-institution in a related proceeding.
Microsoft Corporation v.Proxense, LLC
The PTAB denied Microsoft's request to institute Inter Partes Review against Proxense's patent because a related review was already underway.
Geneoscopy, Inc. v.Exact Sciences Corporation
The PTAB issued a Final Written Decision finding all challenged claims unpatentable under 35 U.S.C. § 103. The Petitioner successfully argued that the claimed colorectal cancer screening method was obvious when combining various prior art references, including Lenhard, Vilkin, Itzkowitz, and Kanaoka.
Dyson Technology Limited et al. v.Omachron Intellectual Property Inc. et al.
Dyson and Omachron have settled their dispute over U.S. Patent 11,910,983 and jointly moved to terminate the inter partes review. The motion cites statutory authority under 35 U.S.C. § 317(a) and public‑policy reasons favoring settlement.
Altice USA, Inc. et al. v.Touchstream Technologies, Inc.
Google (challenger) failed to prove obviousness of Touchstream's 2013 smart‑TV control patent. The PTAB affirmed all challenged claims, leaving the patent fully intact.
Altice USA, Inc. et al. v.Touchstream Technologies, Inc.
Google’s inter partes review of Touchstream’s ’251 patent failed; the Board found no unpatentable subject matter for claims 1, 2, and 5‑9. The petition relied on Muthukumarasamy and Hayward, but the Board concluded the references did not teach the required signal flow or media‑player identification.
Altice USA, Inc. et al. v.Touchstream Technologies, Inc.
Altice USA filed an unopposed motion to withdraw its IPR against Touchstream's streaming patent, arguing the case is still in the preliminary stage and withdrawal would save resources. The patent owner does not object, and the Board has yet to rule.
Dyson Technology Limited et al. v.Omachron Intellectual Property Inc. et al.
Dyson and Omachron settled their inter partes review dispute over U.S. Patent 11,910,983 B2. The Board granted a joint motion to terminate the proceeding and treated the settlement agreement as confidential.
Dyson Technology Limited et al. v.Omachron Intellectual Property Inc. et al.
Dyson and Omachron have settled their IPR dispute over U.S. Patent 11,910,983. They jointly filed a motion to terminate the proceeding and to keep the settlement agreement confidential under statutory provisions.
Dyson Technology Limited et al. v.Omachron Intellectual Property Inc. et al.
Dyson has filed an IPR petition seeking cancellation of Omachron’s vacuum‑cleaner patent (US 11,910,983). The petition alleges obviousness over four prior‑art references and argues discretionary factors favor institution.
Altice USA, Inc. et al. v.Touchstream Technologies, Inc.
Altice USA filed a petition challenging claims of Touchstream Technologies' patent via an IPR proceeding focused on obviousness (103). The petitioner argues that Claims 1-20 are rendered obvious by combining prior art references such as Aldrey and Mahajan. This petition was subsequently joined into an already instituted IPR, continuing the dispute over media content control technology.
Altice USA, Inc. et al. v.Touchstream Technologies, Inc.
Altice USA filed an Inter Partes Review petition challenging 26 claims of Touchstream Technologies' '251 Patent, asserting obviousness under 35 U.S.C. § 103. The petitioner argues that known techniques for translating generic commands into platform-specific code render the claimed media playback control system predictable. This challenge involves complex combinations of prior art references like Aldrey and Mahajan.
Altice USA, Inc. et al. v.Touchstream Technologies, Inc.
The PTAB issued a Final Written Decision finding claims 22-26 unpatentable under § 103(a) based on combinations of prior art (Aldrey and Mahajan). However, the Board upheld the patentability of claims 1-21, concluding that Calvert did not remedy the necessary 'converting' step.
Dealing with a patent challenge?
Whether it's a Section 3(d) rejection, a post-grant opposition, or a FRAND dispute, Arctic's patent litigation team has handled it. Get a strategy call.